Accu-Chek

®

Aviva Expert

Product Overview

Lucy Shelton, Roche Diagnostic

Experience what’s possible.

Multiple Daily Injections

Benefits of therapy

• • • • Basal/bolus or MDI therapy is widely recognised to offer the potential of tight glucose control.

It attempts to closely mimic the patterns of insulin secretion observed in people without diabetes.

When combined with carbohydrate counting, it allows more flexibility with diet and lifestyle.

Particularly beneficial to those people with variable or erratic lifestyles for whom insulin requirements may differ on a daily basis.

2 | www.accu chek.com © 2011 Roche Diagnostics |

Accu-Chek Aviva Expert

Challenges of therapy

Factors to consider for each bolus 3 | www.accu chek.com © 2011 Roche Diagnostics |

Accu-Chek Aviva Expert

Challenges of therapy

A time consuming challenge - 35 times per week, 1800 per year* * Ref: Katherine Barnard and Christopher Parkin, Diabetes Care for Children and Young People Vol.1 No 1 2012: 6-9 • Complex mathematical calculation for each dose.

• Limited access to CHO counting courses.

• Poor numeracy skills common in UK population.

• Large amount of guesswork and active insulin often overlooked.

• Inaccurate bolus calculation can lead to persistent poor diabetes control.

4 | www.accu chek.com © 2011 Roche Diagnostics |

Accu-Chek Aviva Expert

Benefits of bolus advisor system

• Automatically adjusts recommended bolus to safely reach bG targets.

• Individually programmed with personalised settings.

• Accounts for various factors including active insulin, health etc.

• Clinically proven to reduce HbA1c 1 • Reduces fear of hypogylycaemia 2 • Easy, safe and accurate.

1. “Use of an Automated Bolus Calculator in MDI Treated Type 1 Diabetes: The BolusCal Study, a Randomized Controlled Pilot Study” Schmidt S. et al. DIABETES CARE, Feb.2012.

2. Use of an Automated Bolus Calculator Reduces Fear of Hypoglycemia and Improves Confidence in Dosage Accuracy in T1dm Patients Treated with Multiple Daily Insulin Injections, Katharine Barnard et al, Journal of Diabetes Science and Technology, January, 2012.

5 | www.accu chek.com © 2011 Roche Diagnostics |

Accu-Chek Aviva Expert

Benefits of bolus advisor system

• Helps people on MDI therapy to safely and more effectively manage their diabetes.

• Reduces the burden of diabetes self management.

• Contributes to improved diabetes control and quality of life.

• Reduces the risk of acute and long term complications.

• Increases self-efficacy associates with self 6 | www.accu chek.com © 2011 Roche Diagnostics |

Accu-Chek

®

Aviva Expert

• • Results of a patient trial Conducted between June and December 2010 Based on 1412 patients from an on-line survey from patients treated in the UK and ROI • • The results have been: Approved for publication in the

Journal of Diabetes Science and Technology

by Katharine Barnard et al in January 2012* Presented as an abstract at EASD 2011.

* USE OF AN AUTOMATED BOLUS CALCULATOR REDUCES FEAR OF HYPOGLYCEMIA AND IMPROVES CONFIDENCE IN DOSAGE ACCURACY IN T1DM PATIENTS TREATED WITH MULTIPLE DAILY INSULIN INJECTIONS, Katharine Barnard et al, Journal of Diabetes Science and Technology, January, 2012 (in press) chek.co.uk © 2010 Roche www.accu chek.com © 2011 Roche Diagnostics |

Experience what’s possible.

Experience what’s possible.

Accu-Chek Aviva Expert

Patients reported that the Accu-Chek Aviva Expert ® also improved:

Ability to act on BGM results Control of BG levels Achieving treatment targets such as HbA1c Flexibility in meals, exercise, and lifestyle

% = Significantly improved or improved

81% 74% 67% 63%

“HbA1c is down from 10.9 to 8.3 mmol/l and is a great tool for my driving ability and convenience”

www.accu chek.com © 2011 Roche Diagnostics |

Accu-Chek Aviva Expert

for Fixed Dose MDI

• For patients  who do not adjust insulin bolus, and  who are not able to learn to count carbs or calculate their insulin boluses because of limited math skills • By correcting for their bG levels before meals, the system will strive to bring them closer to their target ranges.

• Better engagement with T1 and 2 MDI patients, leading to improved control.

11 | www.accu chek.com © 2011 Roche Diagnostics |